Episode Details

Management is intentionally shrinking the early-stage business to fix margins, while a distressed partner flagged as a "large consumer genetics client" dragged down organic volume.

In ~10 minutes:

* Revenue slides to $3.52B, but Adj. EPS hits $4.07. 📉

* One "bad client" cost ~1% of organic volume.

* Early Development revenue crashes 13.5% YoY.

* "Shrink to grow": Cutting $50M in annual revenue.

* Capex jumping to ~4% to build massive Indiana hub.

It’s a tale of two labs: Central Labs are booming on late-stage trials, while pre-clinical work is being restructured. Management is betting on automation and a delayed PAMA timeline to bridge the gap.

Labcorp (LH) | Q4 FY2025

AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.